The therapeutic potential of CXCR4 antagonists in the treatment of HIV

Bibliography

• MITSUYA H, ERICKSON J: Drug development. A. Discovery and development of antiretroviral therapeutics for HIV infection. In: Textbook of AIDS Medicine. TC Merigan, JG Bartlett, D Bolognesi (Eds), Williams & Wilkins, Baltimore (1999):751–780.
   Google Scholar
• FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872–877.
   PubMed Web of Science ®Google Scholar
• •The first discovery of CXCR4 as a co-receptor of X4-HIV-1 entry.
   Google Scholar
• DENG H, LIU R, ELLMEIER W etal.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661–666.
   Google Scholar
• DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667–673.
   PubMed Web of Science ®Google Scholar
• ALKHATIB G, COMBADIERE C, BRODER CC et al.: A RANTES, MIP-la, MIP-113 receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272: 1955-1958.
   Google Scholar
• CHOE H, FARZAN M, SUN Y et al.: The 3-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 85:1135–1148.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, RUCKER J, YI Y et a/.: A dual-tropic primary HIV-1 isolate that uses fusin and the 3-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 85:1149–1158.
   Google Scholar
• CHAN DC, KIM PS: HIV entry and its inhibition. Cell (1998) 93:681–684.
   PubMed Web of Science ®Google Scholar
• MURAKAMI T, NAKAJIMA T, KOYANAGI Y et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.j Exp. Med. (1997) 186:1389–1393.
   Google Scholar
• ••Identification of T22 as a specific CXCR4 antagonist.
   Google Scholar
• SCHOLS D, STRUYF S, VAN DAMME J, ESTE JA, HENSON G, DE CLERCQ E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. _J. Exp. Med. (1997) 186:1383–1388.
   PubMed Web of Science ®Google Scholar
• • Discovery of another CXCR4 antagonist, AMD3100.
   Google Scholar
• DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor.j. Exp. Med. (1997) 186:1395–1400.
   Google Scholar
• • Discovery of another CXCR4 antagonist, ALX40-4C.
   Google Scholar
• MASUDA M, NAKASHIMA H, UEDA T et al.: A novel anti-HIV synthetic peptide, T-22 aTyr5,12, LysThpolyphemusin II). Biochem. Biophys. Res. Commun. (1992) 189:845–850.
   PubMed Web of Science ®Google Scholar
• ••Discovery of an antiHIV peptide, T22.
   Google Scholar
• NAKASHIMA H, MASUDA M, MURAKAMI T et al.: Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 aTyr-5,12, Lys-71polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother. (1992) 36:1249-1255. Identification of T22 as a virus-cell fusion inhibitor.
   Google Scholar
• NAKAMURA T, FURUNAKA H, MIYATA T et al.: Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab ( Tachypleus tridentatus). j Biol. Chem. (1988) 263:16709–16713.
   PubMed Web of Science ®Google Scholar
• MIYATA T, TOKUNAGA E YONEYA T et al.: Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity. j Biochem. (1989) 106:663–668.
   Google Scholar
• TAMAMURA H, KURODA M, MASUDA M et al.: A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 (lTyr5'12, LysThpolyphemusin II), determined by nuclear magnetic resonance. Biochim. Biophys. Acta (1993) 1163:209–216.
   PubMed Web of Science ®Google Scholar
• NAGASAWA T, KIKUTANI H, KISHIMOTO T: Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Li. USA (1994) 91:2305–2309.
   PubMed Web of Science ®Google Scholar
• BLEUL CC, FARZAN M, CHOE H etal.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829–833.
   Google Scholar
• OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833–835.
   PubMed Web of Science ®Google Scholar
• TASHIRO K, TADA H, HEILKER R, SHIROZU M, NAKANO T, HONJO T: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science (1993) 261:600–603.
   PubMed Web of Science ®Google Scholar
• TAMAMURA H, XU Y, HATTORI T etal.: A low molecular weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. (1998) 253:877–882.
   Google Scholar
• ••Discovery of a downsized CXCR4antagonist T140.
   Google Scholar
• TAMAMURA H, SUGIOKA M, ODAGAKI Y etal.: Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett. (2001) 11:359–362 & 2409.
   Google Scholar
• ICHIYAMA K, HIROSE K, YOKOYAMA S et al.: KRH-1120, a small-CXCR4 antagonistic nonpeptide molecule, with highly potent and selective anti-HIV-1 activity. 13th International AIDS Conference, Durban, South Africa (2000) (Abstract WeOrA535).
   Google Scholar
• MACFARLAND RT et al: An orally bioavailable CXCR4 antagonist for inhibition of HIV replication. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Canada (2000) (Poster 1845).
   Google Scholar
• ENDRES MJ, CLAPHAM PR, MARSH M et al: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell (1996) 87:745–756.
   PubMed Web of Science ®Google Scholar
• XU Y, TAMAMURA H, ARAKAKI R et al: Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res. Hum. Retroviruses (1999) 15:419–427.
   PubMed Web of Science ®Google Scholar
• TAMAMURA H, OMAGARI A, OISHI S et al: Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. (2000) 10:2633–2637.
   PubMed Web of Science ®Google Scholar
• •Pharmacophore identification of T140 and development of more effective compounds.
   Google Scholar
• TAMAMURA H, OMAGARI A, HIRAMATSU K et al.: Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett. (2001) 11:1897–1902.
   PubMed Web of Science ®Google Scholar
• •Development of effective T140 analogues with stability in serum.
   Google Scholar
• TAMAMURA H, ARAKAKI R, FUNAKOSHI H et al.: Effective lowly cytotoxic analogs of an HIV-cell fuion inhibitor, T22 (lTyr5'12, Lys71-polyphemusin II). Bioorg. Med. Chem. (1998) 6:231–238.
   PubMed Web of Science ®Google Scholar
• TAMAMURA H, ISHIHARA T, OYAKE H et al.: Convenient one-pot synthesis of cystine-containing peptides using the trimethylsilyl chloride-dimethylsulfoxide/ trifluoroacetic acid system and its application to the synthesis of bifunctional anti-HIV compounds. j Chem. Soc. Perkin. Trans. 1 (1998):495–500.
   Google Scholar
• TAMAMURA H, OMAGARI A, HIRAMATSU K et al.: Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation. Bioorg. Med. Chem. (2001) 9:2179–2187.
   PubMed Web of Science ®Google Scholar
• •Synthesis of twin drugs based on CXCR4 antagonist-AZT conjugation.
   Google Scholar
• TRKOLA A, DRAGIC T, ARTHOS J et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 384:184–187.
   PubMed Web of Science ®Google Scholar
• SCHOLS D, ESTE JA, CABRERA C, DE CLERCQ E: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1a contains mutations in the envelope gp120, but does not show a switch in coreceptor use. j Viral (1998) 72:4032–4037.
   PubMed Web of Science ®Google Scholar
• DE VREESE K, KOFLER-MONGOLD V, LEUTGEB C etal.: The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. Viral (1996) 70:689–696.
   Google Scholar
• KANBARA K, SATO S, TANUMA J et al: Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res. Hum. Retroviruses (2001) 17:615–622.
   PubMed Web of Science ®Google Scholar
• •Identification of the difficulty of the generation of a T140-resistant HIV.
   Google Scholar
• ZHANG W, NAVENOT JM, HARIBABU B et al.: A point mutation that confers constitutive activity to CXCR4 reveals T140 is an inverse agonist and AMD3100 and ALX40-4C are weak partial agonists. Biol. Chem. (2002) 277:24515–24521.
   Web of Science ®Google Scholar
• •T140 is an inverse agonist against CXCR4.
   Google Scholar
• TAMAMURA H, YAMASHITA M, NAKAJIMA Y et al.: Regiospecific ring-opening reactions of P-aziridinyl a43-enoates with acids: application to the stereoselective synthesis of a couple of diastereoisomeric (E)-alkene dipeptide isosteres from a single P-aziridinyl a43-enoate and to the convenient preparation of amino alcohols bearing a43-unsaturated ester groups. I Chem .Soc. Perkin. Trans. 1 (1999):2983–2996.
   Google Scholar
• TAMAMURA H, HIRAMATSU K, MIYAMOTO K et al.: Synthesis and evaluation of pseudopeptide analogs of a specific CXCR4 inhibitor, T140: the insertion of an (4-alkene dipeptide isostere into the I3I1-turn moiety. Bioorg. Med. Chem. Lett. (2002) 12:923–928.
   PubMed Web of Science ®Google Scholar
• MOLLER A, HOMEY B, SOTO H etal.: Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410:50–56.
   Google Scholar
• KOSHIBA T, HOSOTANI R, MIYAMOTO Y et al.: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. (2000) 6:3530–3535.
   PubMed Web of Science ®Google Scholar
• SEHGAL A, KEENER C, BOYNTON AL,WARRICK J, MURPHY GP: CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. I Surg. aka (1998) 69:99–104.
   Google Scholar
• SEHGAL A, RICKS S, BOYNTON AL, WARRICK J, MURPHY GP: Molecular characterization of CXCR-4: a potential brain tumor-associated gene. I Surg. arca (1998) 69:239–248.
   Google Scholar
• REMPEL SA, DUDAS S, GE S, GUTIERREZ JA: Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res. (2000) 6:102–111.
   PubMed Web of Science ®Google Scholar
• GEMINDER H, SAGI-ASSIF 0, GOLDBERG L et al.: A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. I Immurrol (2001) 167:4747–4757.
   Google Scholar
• OH JW, DRABIK K, KUTSCH 0, CHOI C, TOUSSON A, BENVENISTE EN: CXC chemokine receptor 4 expression and function in human astroglioma cells. Immurrol (2001) 166:2695–2704.
   Google Scholar
• SCOTTON CJ, WILSON JL, MILLIKEN D, STAMP G, BALKWILL FR: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. (2001) 61:4961–4965.
   Google Scholar
• TAICHMAN RS, COOPER C, KELLER ET, PIENTA KJ, TAICHMAN NS, MCCAULEY LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. (2002) 62:1832–1837.
   PubMed Web of Science ®Google Scholar
• ROBLEDO MM, BARTOLOME RA, LONGO N et al: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. I Biol. Chem. (2001) 276:45098–45105.
   Web of Science ®Google Scholar
• SCHRADER AJ, LECHNER 0, TEMPLIN M et al.: CXCR4/CXCL12 expression and signalling in kidney cancer. Br .I Cancer (2002) 86:1250–1256.
   Google Scholar
• MOHLE R, BAUTZ F, RAFII S, MOORE MA, BRUGGER W, KANZ L: The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood (i998) 91:4523-4530.
   Google Scholar
• BURGER JA, BURGER M, KIPPS TJ: Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood(i999) 94:3658-3667.
   Google Scholar
• MOHLE R, FAILENSCHMID C, BAUTZ F, KANZ L: Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia (1999) 13: 1954-1959.
   Google Scholar
• MOHLE R, SCHITTENHELM M, FAILENSCHMID C et al.: Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br j Haematol. (2000) 110:563–572.
   PubMed Web of Science ®Google Scholar
• DURIG J, SCHMUCKER U, DUHRSEN U: Differential expression of chemokine receptors in B cell malignancies. Leukemia (2001) 15:752–756.
   PubMed Web of Science ®Google Scholar
• CRAZZOLARA R, KRECZY A, MANN G et al.: High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br j Haematol. (2001) 115:545–553.
   PubMed Web of Science ®Google Scholar
• BERTOLINI E DELEAGNOLA C, MANCUSO P et al.: CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res. (2002) 62:3106–3112.
   PubMed Web of Science ®Google Scholar
• NANKI T, HAYASHIDA K, EI- GABALAWY HS et al.: Stromal cell-derived factor-l-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. I Immurrol. (2000) 165:6590–6598.
   Google Scholar
• BABA M, NISHIMURA 0, KANZAKI M et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Nati Acad. Sri. USA (1999) 96:5698–5703.
   Google Scholar
• MAEDA K, YOSHIMURA K, SHIBAYAMA S et al.: Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. Biol. Chem. (2001) 276:35194–35200.
   Web of Science ®Google Scholar
• STRIZKI JM, XU S, WAGNER NE et al.:SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Nati Acad. Sri. USA (2001) 98:12718–12723.
   PubMed Web of Science ®Google Scholar
• DORN CP FINKE PE, OATES B et al.:Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4- Ipiperidin- 1 -yfi butanes. Bioorg. Med. Chem. Lett. (2001) 11:259–264.
   Google Scholar
• CHAN DC, FASS D, BERGER JM, KIMPS: Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 89:263–273.
   PubMed Web of Science ®Google Scholar
• WILD CT, SHUGARS DC, GREEN WELL TK et al.: Peptides corresponding to a predictive alpha-helical domain of human-immunodeficiency-virus type-1 gp41 are potent inhibitors of virus-infection. Proc. Natl. Acad. Sri. USA (1994) 91:9770–9774.
   Google Scholar
• KILBY JM: Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. Expert Opin. Investig. Drugs (1999) 8:1157–1170.
   PubMedGoogle Scholar
• OTAKA A, NAKAMURA M, NAMEKI D etal.: Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem. Int. Ed. (2002) 41:2937–2940.
   Google Scholar